TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06917313: FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Sponsor: Yale University · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 92 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06917313 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06917313 Rescue Dossier →